In March ABL announced the appointment of Stéphanie Colloud as General Manager and Chief Operating Officer (COO) for Europe. In her new role, she will be responsible for operations at the Lyon and Strasbourg development and clinical production sites. Colloud’s priorities include strengthening ABL’s R&D work in its GMP production platforms for Adeno Associated Viruses (AAV) and LentiViruses (LV), both internally and with partner companies.
www.abl-biomanufacturing.com
